Symbols / ZLAB Stock $18.58 -2.72% Zai Lab Limited

Healthcare • Biotechnology • China • NGM
ZLAB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Ying Du Ph.D.
Exch · Country NGM · China
Market Cap 2.09B
Enterprise Value 21.03B
Income -178.12M
Sales 453.28M
FCF (ttm) -73.36M
Book/sh 6.47
Cash/sh 0.59
Employees 1,784
Insider 10d —
IPO Sep 20, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -10.64
PEG —
P/S 4.61
P/B 2.87
P/C —
EV/EBITDA -92.64
EV/Sales 46.40
Quick Ratio 1.84
Current Ratio 2.40
Debt/Eq 35.03
LT Debt/Eq —
EPS (ttm) -1.70
EPS next Y -1.75
EPS Growth —
Revenue Growth -6.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -13.36%
ROE -24.19%
ROIC —
Gross Margin 8.11%
Oper. Margin -69.66%
Profit Margin -39.29%
Shs Outstand 112.35M
Shs Float 979.08M
Insider Own 1.96%
Instit Own 29.20%
Short Float 4.05%
Short Ratio 5.51
Short Interest 4.45M
52W High 44.34
vs 52W High -58.10%
52W Low 15.96
vs 52W Low 16.42%
Beta 0.84
Impl. Vol. 33.76%
Rel Volume 0.28
Avg Volume 778.54K
Volume 220.67K
Target (mean) $33.78
Tgt Median $32.24
Tgt Low $21.60
Tgt High $52.00
# Analysts 12
Recom Strong_buy
Prev Close $19.10
Price $18.58
Change -2.72%
About

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$33.78
Mean price target
2. Current target
$18.58
Latest analyst target
3. DCF / Fair value
$-11.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.58
Low
$21.60
High
$52.00
Mean
$33.78

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-08 main Citigroup Buy → Buy $44
2026-03-18 main JP Morgan Overweight → Overweight $32
2026-02-27 main Cantor Fitzgerald Overweight → Overweight $37
2026-02-05 main JP Morgan Overweight → Overweight $39
2026-01-07 init UBS — → Buy $35
2025-08-11 main Citigroup Buy → Buy $69
2025-06-30 main Leerink Partners Outperform → Outperform $75
2025-03-27 reit Cantor Fitzgerald Overweight → Overweight —
2025-03-13 main JP Morgan Overweight → Overweight $51
2025-03-07 init Scotiabank — → Sector Outperform $55
2025-03-03 down B of A Securities Buy → Neutral $36
2024-10-25 reit Cantor Fitzgerald — → Overweight —
2024-10-21 main JP Morgan Overweight → Overweight $44
2024-08-07 reit Cantor Fitzgerald — → Overweight —
2024-07-12 main JP Morgan Overweight → Overweight $38
2024-07-01 reit Cantor Fitzgerald — → Overweight —
2024-06-25 reit Cantor Fitzgerald — → Overweight —
2024-02-29 main Citigroup Buy → Buy $66
2023-12-14 init Morgan Stanley — → Overweight $48
2023-11-30 main JP Morgan Overweight → Overweight $66
News
RSS: Latest ZLAB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-18 DU YING SAMANTHA Chief Executive Officer — 100,000 $1.74 $174,000
2026-05-18 DU YING SAMANTHA Chief Executive Officer — 100,000 $19.00 $1,986,875
2026-05-14 DU YING SAMANTHA Chief Executive Officer — 100,000 $1.74 $174,000
2026-05-14 DU YING SAMANTHA Chief Executive Officer — 100,000 $19.44 $2,003,044
2026-05-14 EDMONDSON FRAZOR TITUS III Officer — 3,517 $20.19 $71,008
2026-04-06 DU YING SAMANTHA Chief Executive Officer — 2,653 $20.45 $54,249
2026-04-06 EDMONDSON FRAZOR TITUS III Officer — 1,224 $20.45 $25,028
2026-04-06 CHEN YAJING Chief Financial Officer — 853 $20.45 $17,442
2026-04-06 AMADO RAFAEL President — 2,739 $20.45 $56,007
2026-04-06 SMILEY JOSHUA L President — 3,017 $20.45 $61,692
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
460.16
+15.33%
398.99
+49.59%
266.72
+24.03%
215.04
Operating Revenue
499.21
+17.40%
425.23
+42.26%
298.91
+26.46%
236.38
Cost Of Revenue
191.08
+29.23%
147.86
+54.32%
95.82
+29.45%
74.02
Reconciled Cost Of Revenue
191.08
+29.23%
147.86
+54.32%
95.82
+29.45%
74.02
Gross Profit
269.07
+7.15%
251.13
+46.94%
170.90
+21.19%
141.02
Operating Expense
492.65
-6.18%
525.08
-3.66%
545.04
+2.09%
533.91
Research And Development
220.90
-5.80%
234.50
-11.80%
265.87
-7.17%
286.41
Selling General And Administration
277.61
-7.08%
298.74
+6.08%
281.61
+8.74%
258.97
Selling And Marketing Expense
—
123.78
+14.38%
108.22
+75.93%
61.51
General And Administrative Expense
277.61
-7.08%
298.74
+6.08%
281.61
+8.74%
258.97
Salaries And Wages
165.00
-5.69%
174.96
+0.90%
173.39
+7.00%
162.04
Other Gand A
112.60
-9.03%
123.78
+14.38%
108.22
+11.65%
96.93
Other Operating Expenses
-5.86
+28.25%
-8.17
-235.80%
-2.43
+78.79%
-11.47
Total Expenses
683.73
+1.60%
672.93
+5.01%
640.86
+5.42%
607.93
Operating Income
-223.57
+18.39%
-273.95
+26.78%
-374.14
+4.77%
-392.89
Total Operating Income As Reported
-229.43
+18.67%
-282.12
+23.04%
-366.57
+9.34%
-404.36
EBITDA
-158.25
+34.88%
-242.99
+25.37%
-325.59
+25.12%
-434.84
Normalized EBITDA
-177.84
+21.95%
-227.86
+28.96%
-320.74
+15.25%
-378.44
Reconciled Depreciation
15.01
+26.60%
11.86
+31.31%
9.03
+9.75%
8.23
EBIT
-173.25
+32.02%
-254.85
+23.84%
-334.62
+24.48%
-443.06
Total Unusual Items
19.59
+229.42%
-15.14
-212.10%
-4.85
+91.40%
-56.40
Total Unusual Items Excluding Goodwill
19.59
+229.42%
-15.14
-212.10%
-4.85
+91.40%
-56.40
Special Income Charges
0.00
0.00
-100.00%
10.00
0.00
Net Income
-175.54
+31.73%
-257.10
+23.17%
-334.62
+24.51%
-443.29
Pretax Income
-178.46
+30.59%
-257.10
+23.17%
-334.62
+24.48%
-443.06
Net Non Operating Interest Income Expense
27.84
-20.12%
34.85
-12.43%
39.80
+172.92%
14.58
Interest Expense Non Operating
5.21
+131.10%
2.25
0.00
0.00
Net Interest Income
27.84
-20.12%
34.85
-12.43%
39.80
+172.92%
14.58
Interest Expense
5.21
+131.10%
2.25
0.00
0.00
Interest Income Non Operating
33.05
-10.93%
37.10
-6.76%
39.80
+172.92%
14.58
Interest Income
33.05
-10.93%
37.10
-6.76%
39.80
+172.92%
14.58
Other Income Expense
17.27
+195.90%
-18.01
-6400.72%
-0.28
+99.57%
-64.76
Other Non Operating Income Expenses
-0.41
-112.67%
3.23
+81.33%
1.78
+200.34%
0.59
Gain On Sale Of Security
19.59
+229.42%
-15.14
-1.93%
-14.85
+73.67%
-56.40
Tax Provision
-2.93
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.32
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-175.54
+31.73%
-257.10
+23.17%
-334.62
+24.51%
-443.29
Net Income From Continuing Operation Net Minority Interest
-175.54
+31.73%
-257.10
+23.17%
-334.62
+24.51%
-443.29
Net Income From Continuing And Discontinued Operation
-175.54
+31.73%
-257.10
+23.17%
-334.62
+24.51%
-443.29
Net Income Continuous Operations
-175.54
+31.73%
-257.10
+23.17%
-334.62
+24.51%
-443.29
Normalized Income
-194.81
+19.49%
-241.97
+26.63%
-329.77
+14.76%
-386.88
Net Income Common Stockholders
-175.54
+31.73%
-257.10
+23.17%
-334.62
+24.51%
-443.29
Diluted EPS
-1.60
+38.46%
-2.60
+25.71%
-3.50
+23.91%
-4.60
Basic EPS
-1.60
+38.46%
-2.60
+25.71%
-3.50
+23.91%
-4.60
Basic Average Shares
109.53
+10.70%
98.95
+2.39%
96.64
+0.87%
95.81
Diluted Average Shares
109.53
+10.70%
98.95
+2.39%
96.64
+0.87%
95.81
Diluted NI Availto Com Stockholders
-175.54
+31.73%
-257.10
+23.17%
-334.62
+24.51%
-443.29
Earnings From Equity Interest
-1.91
+68.68%
-6.11
-318.90%
2.79
+131.16%
-8.95
Earnings From Equity Interest Net Of Tax
—
0.00
0.00
+100.00%
-0.22
Gain On Sale Of PPE
0.00
0.00
-100.00%
10.00
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,172.38
-1.13%
1,185.75
+14.42%
1,036.30
-15.07%
1,220.14
Current Assets
1,019.29
-2.97%
1,050.48
+11.80%
939.61
-16.43%
1,124.34
Cash Cash Equivalents And Short Term Investments
689.57
-11.56%
779.67
-3.32%
806.45
-20.03%
1,008.47
Cash And Cash Equivalents
679.57
+51.13%
449.67
-43.09%
790.15
-21.65%
1,008.47
Cash Equivalents
1.22
+4.83%
1.16
+5.36%
1.10
+5.06%
1.05
Cash Financial
678.36
+51.25%
448.51
-43.16%
789.05
-21.68%
1,007.42
Other Short Term Investments
10.00
-96.97%
330.00
+1924.54%
16.30
0.00
Receivables
118.28
+32.29%
89.41
+36.85%
65.33
+34.51%
48.57
Accounts Receivable
106.12
+24.58%
85.18
+43.88%
59.20
+48.13%
39.96
Gross Accounts Receivable
106.15
+24.58%
85.20
+43.89%
59.22
+48.14%
39.97
Allowance For Doubtful Accounts Receivable
-0.03
-24.00%
-0.03
-47.06%
-0.02
-54.55%
-0.01
Inventory
74.75
+87.45%
39.88
-11.05%
44.83
+41.76%
31.62
Raw Materials
23.11
+74.15%
13.27
-24.85%
17.66
-7.22%
19.03
Work In Process
5.79
+127.63%
2.54
-43.09%
4.47
+925.23%
0.44
Finished Goods
45.85
+90.53%
24.06
+6.00%
22.70
+86.76%
12.16
Prepaid Assets
—
—
—
—
Restricted Cash
100.00
+0.00%
100.00
0.00
—
Other Current Assets
36.68
-11.66%
41.53
+80.59%
23.00
-35.54%
35.67
Total Non Current Assets
153.10
+13.18%
135.27
+39.91%
96.69
+0.92%
95.80
Net PPE
66.54
-4.20%
69.46
+1.12%
68.69
-12.80%
78.77
Gross PPE
108.70
+2.00%
106.58
+7.84%
98.83
-1.99%
100.83
Accumulated Depreciation
-42.16
-13.59%
-37.12
-23.17%
-30.14
-36.58%
-22.06
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
24.60
0.00
—
—
Machinery Furniture Equipment
1.40
-1.75%
1.43
+14.45%
1.25
+5.68%
1.18
Construction In Progress
0.55
-97.80%
25.13
+3.06%
24.38
-4.93%
25.65
Other Properties
68.10
-0.89%
68.72
+11.15%
61.83
-1.41%
62.71
Leases
14.05
+24.26%
11.31
-0.57%
11.37
+0.63%
11.30
Goodwill And Other Intangible Assets
79.00
+34.04%
58.93
+258.09%
16.46
+95.86%
8.40
Other Intangible Assets
79.00
+34.04%
58.93
+258.09%
16.46
+95.86%
8.40
Investments And Advances
—
3.12
-66.21%
9.22
+43.37%
6.43
Non Current Accounts Receivable
—
1.35
—
—
Non Current Deferred Assets
3.39
0.00
—
—
Non Current Deferred Taxes Assets
3.39
0.00
—
—
Non Current Prepaid Assets
—
1.28
+6.20%
1.21
-13.40%
1.40
Other Non Current Assets
4.17
-39.41%
6.88
+518.33%
1.11
+38.61%
0.80
Total Liabilities Net Minority Interest
456.88
+32.49%
344.86
+43.58%
240.18
+37.60%
174.54
Current Liabilities
416.17
+39.01%
299.38
+47.43%
203.07
+45.21%
139.84
Payables And Accrued Expenses
198.22
+29.32%
153.27
-19.59%
190.61
+48.06%
128.74
Payables
147.40
+38.39%
106.51
-19.59%
132.45
+56.70%
84.53
Accounts Payable
141.61
+40.34%
100.91
-10.70%
112.99
+71.27%
65.97
Other Payable
0.49
+8.24%
0.45
-81.85%
2.47
-53.05%
5.27
Current Accrued Expenses
50.82
+8.67%
46.77
-19.59%
58.16
+31.54%
44.21
Total Tax Payable
5.30
+2.89%
5.15
-69.66%
16.99
+27.89%
13.28
Current Debt And Capital Lease Obligation
210.87
+50.88%
139.76
+1867.33%
7.10
+0.77%
7.05
Current Debt
204.53
+55.29%
131.71
—
—
Current Capital Lease Obligation
6.34
-21.17%
8.05
+13.29%
7.10
+0.77%
7.05
Other Current Liabilities
7.07
+11.37%
6.35
+18.66%
5.35
+32.04%
4.05
Total Non Current Liabilities Net Minority Interest
40.72
-10.45%
45.47
+22.53%
37.11
+6.94%
34.70
Long Term Debt And Capital Lease Obligation
13.38
-2.38%
13.71
+70.40%
8.05
-39.69%
13.34
Long Term Capital Lease Obligation
13.38
-2.38%
13.71
+70.40%
8.05
-39.69%
13.34
Non Current Deferred Liabilities
27.33
-13.04%
31.43
+9.38%
28.74
+34.54%
21.36
Non Current Deferred Revenue
27.33
-13.04%
31.43
+9.38%
28.74
+34.54%
21.36
Other Non Current Liabilities
—
0.33
+0.00%
0.33
—
Stockholders Equity
715.50
-14.91%
840.90
+5.62%
796.12
-23.86%
1,045.60
Common Stock Equity
715.50
-14.91%
840.90
+5.62%
796.12
-23.86%
1,045.60
Capital Stock
0.01
+0.00%
0.01
+16.67%
0.01
+0.00%
0.01
Common Stock
0.01
+0.00%
0.01
+16.67%
0.01
+0.00%
0.01
Share Issued
1,113.82
+2.88%
1,082.61
+10.79%
977.15
+1.53%
962.46
Ordinary Shares Number
1,106.39
+2.66%
1,077.70
+10.85%
972.24
+1.25%
960.22
Treasury Shares Number
7.43
+51.32%
4.91
+0.00%
4.91
+119.66%
2.24
Additional Paid In Capital
3,343.47
+2.43%
3,264.30
+9.71%
2,975.30
+2.84%
2,893.12
Retained Earnings
-2,628.62
-7.16%
-2,453.08
-11.71%
-2,195.98
-17.98%
-1,861.36
Gains Losses Not Affecting Retained Earnings
29.70
-41.21%
50.52
+34.26%
37.63
+46.49%
25.68
Treasury Stock
29.05
+39.44%
20.84
+0.00%
20.84
+75.74%
11.86
Other Equity Adjustments
29.70
-41.21%
50.52
+34.26%
37.63
+46.49%
25.68
Total Equity Gross Minority Interest
715.50
-14.91%
840.90
+5.62%
796.12
-23.86%
1,045.60
Total Capitalization
715.50
-14.91%
840.90
+5.62%
796.12
-23.86%
1,045.60
Working Capital
603.12
-19.70%
751.10
+1.98%
736.54
-25.19%
984.49
Invested Capital
920.03
-5.41%
972.61
+22.17%
796.12
-23.86%
1,045.60
Total Debt
224.26
+46.12%
153.47
+912.94%
15.15
-25.70%
20.39
Capital Lease Obligations
19.73
-9.33%
21.76
+43.62%
15.15
-25.70%
20.39
Net Tangible Assets
636.50
-18.60%
781.96
+0.30%
779.66
-24.83%
1,037.19
Tangible Book Value
636.50
-18.60%
781.96
+0.30%
779.66
-24.83%
1,037.19
Line Of Credit
204.53
+55.29%
131.71
0.00
—
Notes Receivable
12.17
+187.48%
4.23
-30.99%
6.13
-28.74%
8.61
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-150.79
+29.82%
-214.87
-8.42%
-198.18
+46.09%
-367.64
Cash Flow From Continuing Operating Activities
-150.79
+29.82%
-214.87
-8.42%
-198.18
+46.09%
-367.64
Net Income From Continuing Operations
-175.54
+31.73%
-257.10
+23.17%
-334.62
+24.51%
-443.29
Depreciation Amortization Depletion
15.01
+26.60%
11.86
+31.31%
9.03
+9.75%
8.23
Depreciation And Amortization
15.01
+26.60%
11.86
+31.31%
9.03
+9.75%
8.23
Other Non Cash Items
3.69
-34.10%
5.60
+5.15%
5.33
-7.36%
5.75
Stock Based Compensation
65.60
-7.15%
70.65
-11.28%
79.63
+29.90%
61.30
Provisionand Write Offof Assets
0.01
-25.00%
0.01
+33.33%
0.01
+500.00%
0.00
Asset Impairment Charge
12.29
+1407.73%
0.81
-20.87%
1.03
+115.93%
0.48
Operating Gains Losses
-19.05
-222.19%
15.59
+238.84%
4.60
-93.04%
66.14
Unrealized Gain Loss On Investment Securities
1.91
-68.68%
6.11
+318.90%
-2.79
-131.16%
8.95
Net Foreign Currency Exchange Gain Loss
-19.59
-229.42%
15.14
+1.93%
14.85
-73.67%
56.40
Gain Loss On Sale Of PPE
0.54
+19.65%
0.45
+104.42%
-10.25
-1930.18%
0.56
Change In Working Capital
-54.71
+20.01%
-68.39
-272.68%
39.61
+159.79%
-66.25
Change In Receivables
-29.98
-18.92%
-25.21
-42.54%
-17.69
-170.37%
25.14
Changes In Account Receivables
-18.93
+29.82%
-26.98
-34.61%
-20.04
-562.82%
4.33
Change In Inventory
-47.03
-1307.08%
3.90
+126.14%
-14.91
+3.09%
-15.38
Change In Prepaid Assets
5.06
+127.01%
-18.73
-252.94%
12.25
+161.90%
-19.79
Change In Payables And Accrued Expense
19.93
+1002.04%
-2.21
-106.00%
36.80
+168.44%
-53.77
Change In Payable
19.93
+1002.04%
-2.21
-106.00%
36.80
+168.44%
-53.77
Change In Account Payable
19.93
+1002.04%
-2.21
-106.00%
36.80
+168.44%
-53.77
Change In Other Working Capital
0.37
-92.79%
5.15
-54.73%
11.37
+924.37%
-1.38
Change In Other Current Liabilities
-3.05
+90.25%
-31.28
-365.45%
11.78
+1208.56%
-1.06
Investing Cash Flow
307.87
+182.06%
-375.19
-3381.75%
-10.78
-102.57%
420.02
Cash Flow From Continuing Investing Activities
307.87
+182.06%
-375.19
-3381.75%
-10.78
-102.57%
420.02
Net PPE Purchase And Sale
-8.01
-42.40%
-5.63
-76.04%
-3.20
+87.00%
-24.59
Purchase Of PPE
-8.10
-43.20%
-5.66
+21.56%
-7.21
+70.67%
-24.59
Sale Of PPE
0.09
+200.00%
0.03
-99.28%
4.01
0.00
Capital Expenditure
-13.42
+78.18%
-61.52
-624.56%
-8.49
+66.01%
-24.98
Net Investment Purchase And Sale
321.20
+202.39%
-313.70
-1824.54%
-16.30
-103.66%
445.00
Purchase Of Investment
-10.00
+96.97%
-330.00
-146.27%
-134.00
+48.52%
-260.27
Sale Of Investment
331.20
+1931.92%
16.30
-86.15%
117.70
-83.31%
705.27
Net Business Purchase And Sale
—
—
0.00
0.00
Purchase Of Business
—
—
0.00
0.00
Net Intangibles Purchase And Sale
-5.32
+90.47%
-55.87
-740.58%
8.72
+2285.71%
-0.40
Purchase Of Intangibles
-5.32
+90.47%
-55.87
-4267.87%
-1.28
-220.55%
-0.40
Financing Cash Flow
72.35
-79.32%
349.89
+5538.97%
-6.43
-271.85%
-1.73
Cash Flow From Continuing Financing Activities
72.35
-79.32%
349.89
+5538.97%
-6.43
-271.85%
-1.73
Net Issuance Payments Of Debt
67.94
-48.26%
131.32
0.00
0.00
Issuance Of Debt
206.84
+57.16%
131.61
0.00
0.00
Repayment Of Debt
-138.89
-48805.99%
-0.28
0.00
0.00
Short Term Debt Issuance
206.84
+57.16%
131.61
0.00
0.00
Short Term Debt Payments
-138.89
-48805.99%
-0.28
0.00
0.00
Net Short Term Debt Issuance
67.94
-48.26%
131.32
0.00
0.00
Net Common Stock Issuance
0.00
-100.00%
217.35
0.00
0.00
Proceeds From Stock Option Exercised
13.68
+327.34%
3.20
+35.08%
2.37
-59.64%
5.87
Net Other Financing Charges
-9.27
-367.27%
-1.98
+77.47%
-8.80
-15.82%
-7.60
Changes In Cash
229.43
+195.53%
-240.17
-11.51%
-215.39
-525.30%
50.64
Effect Of Exchange Rate Changes
0.48
+254.19%
-0.31
+88.18%
-2.62
+58.21%
-6.27
Beginning Cash Position
550.78
-30.39%
791.26
-21.60%
1,009.27
+4.60%
964.90
End Cash Position
780.69
+41.74%
550.78
-30.39%
791.26
-21.60%
1,009.27
Free Cash Flow
-164.21
+40.59%
-276.39
-33.74%
-206.67
+47.36%
-392.63
Interest Paid Supplemental Data
4.88
+141.37%
2.02
0.00
0.00
Common Stock Issuance
0.00
-100.00%
217.35
0.00
0.00
Earnings Losses From Equity Investments
—
6.11
+318.90%
-2.79
-130.40%
9.17
Issuance Of Capital Stock
0.00
-100.00%
217.35
0.00
0.00
Sale Of Intangibles
0.00
0.00
-100.00%
10.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category